Evommune (EVMN) Company Profile

Complete business overview, executive team, trading details, and corporate information.

Evommune, Inc.

EVMN•New York Stock Exchange•Healthcare•Biotechnology

About Evommune

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.

Stock Details

ExchangeNew York Stock Exchange (NYSE)

CurrencyUSD - USD

TypeStock

SubtypeCommon Stock

Contact Information

Websitewww.evommune.com

Phone(925) 247-4481

Address

1891 Page Mill Road Palo Alto, California 94304 United States

Corporate Identifiers

CIK0002044725

CUSIP30054Y107

ISINUS30054Y1073

EIN85-0742575

SIC2834

Leadership Team & Key Executives

Luis C. Pena

Founder, President, Chief Executive Officer and Director

Kyle Carver CPA, M.B.A.

Chief Financial Officer

Gregory S. Moss Esq.

Chief Business and Legal Officer, Corporate Secretary and Chief Compliance Officer

Dr. Eugene Andrew Bauer M.D.

Co-Founder, Chief Medical Officer and Director

Dr. Jeegar Patel Ph.D.

Chief Scientific Officer

Janice Drew M.P.H.

Chief of Development Operations

Dr. Lou Sehl Ph.D.

Senior Vice President of Technical Operations

Dr. Daniel J. Burge M.d.

Senior Vice President of Clinical Development

J. Mark Jackson M.D.